Download Free Hypersomnolence In A Rat Model Of Obesity Book in PDF and EPUB Free Download. You can read online Hypersomnolence In A Rat Model Of Obesity and write the review.

Methods. Nine pair of age-matched lean and obese adult male Zucker rats were implanted with EEG and EMG electrodes, habituated, and had a 24 hour recording of sleep-wake patterns analyzed in ten second epochs. Delta, theta, and sigma power were normalized and computed for each animal during the entire 24 hour period, during six hours in the day (10 am-4 pm), and during six hours at night (10 pm-4 am).
Clinical practice related to sleep problems and sleep disorders has been expanding rapidly in the last few years, but scientific research is not keeping pace. Sleep apnea, insomnia, and restless legs syndrome are three examples of very common disorders for which we have little biological information. This new book cuts across a variety of medical disciplines such as neurology, pulmonology, pediatrics, internal medicine, psychiatry, psychology, otolaryngology, and nursing, as well as other medical practices with an interest in the management of sleep pathology. This area of research is not limited to very young and old patientsâ€"sleep disorders reach across all ages and ethnicities. Sleep Disorders and Sleep Deprivation presents a structured analysis that explores the following: Improving awareness among the general public and health care professionals. Increasing investment in interdisciplinary somnology and sleep medicine research training and mentoring activities. Validating and developing new and existing technologies for diagnosis and treatment. This book will be of interest to those looking to learn more about the enormous public health burden of sleep disorders and sleep deprivation and the strikingly limited capacity of the health care enterprise to identify and treat the majority of individuals suffering from sleep problems.
"Education, arts and social sciences, natural and technical sciences in the United States and Canada".
Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually. Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasizes what results mean to the overall drug discovery process Explores issues in clinical trial design and conductance in each therapeutic area Psychiatric Disorders is available for purchase individually.
Animal and Translational Models for CNS Drug Discovery combines the experience of academic, clinical and pharmaceutical neuroscientists in a unique collaborative approach to provide a greater understanding of the relevance of animal models of neuropsychiatric disorders and their role as translational tools for the discovery of CNS drugs being developed for the treatment of these disorders. The focus of this three-volume series of essays is to present a consensual picture of the translational value of animal models from leading experts actively involved in the use of animal models for understanding fundamental neurobiology of CNS disorders and the application of this knowledge to CNS drug discovery, and clinical investigators involved in clinical trials, drug development and eventual registration of novel pharmaceuticals. Each volume of the Animal and Translational Models for CNS Drug Discovery series is dedicated to the development and use of animal models in key therapeutic areas in psychiatric, neurologic and reward deficit disorders. Each volume has introductory chapters expressing the view of the role and relevance of animal models for CNS drug discovery and development from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in relevant therapeutic areas and discusses the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. - Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process - Critical evaluation of animal and translational models improving transition from drug discovery and clinical development - Emphasizes what results mean to the overall drug discovery process - Explores issues in clinical trial design and conductance in each therapeutic area - Each volume is available for purchase individually.
Almost fifty years ago, in 1956, three researchers of the University of Zurich, Andrea Prader, Alexis Labhart and Heinrich Willi, first described what is now called the Prader-Willi Syndrome (PWS). The study and the therapy of this syndrome have progressed so rapidly in the past years that the decision was made to share recent advances with the scientific community and to address topics of future research at an international meeting. The results of this meeting are presented in this book. PWS results from a paternally derived deletion or an imprinting defect on chromosome 15. During their first two years of life patients with PWS suffer from muscle weakness, feeding problems and developmental delay. From the age of two years onwards they develop an almost insatiable appetite and suffer from obesity, short stature, hypogonadism and behavior problems. As it is becoming increasingly obvious that PWS is a multisystemic disorder, improving the quality of life of patients and their families requires broad professional support. While growth hormone therapy influences growth and body composition, many other problems such as insufficient satiation, hypoactivity, behavioral difficulties, speech problems and mental retardation remain to be addressed. Parents need psychological support in their daily battle against the eating disorder and the behavioral problems of their child. A comprehensive team approach will yield the best results for both patients and their parents. PWS research may also contribute to basic medical research by providing new insights into the metabolism of obese patients, whose obesity is caused by factors other than PWS. In this way, PWS may be used as a model for obesity.
Sleep disorder is a rampant problem in the US, with over 40 million Americans currently diagnosed according to the NIH. There is a clear association between sleep disorder and a wide range of other human disorders –performance deficiencies, psychiatric illnesses, heart disease, obesity and more – but in spite of this there is not yet a convenient overview on the market detailing the impact of obesity, age, diabetes and diet on sleep duration and attendant health outcomes. This volume focuses on the interaction between sleep and these factors, with special attention being paid to the potential for neurological modulation of sleep via diet. The volume aid readers in understanding the role each of these factors plays in sleep architecture and its regulation by circadian biology and neurology. Aids in understanding the impact of age, diet, obesity and disease on sleep Offers focus on neurological changes that affect metabolism Explores diabetes induced sleep problems Aid to understanding the multifactorial causes of age-related sleep dysfunction Addresses selected studies of nutraceuticals affecting sleep for potential application clinically Discusses major impact on sleep disorders by caffeine and alcohol
​According to the World Health Organization, the epidemic of global obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults were overweight, over 650 million of which were obese. Being overweight and obese has been linked to a number of non-communicable, chronic diseases. Pathophysiology of Obesity-Induced Health Complications is a compilation of review articles dedicated to describe co-morbidities associated with obesity. The wide range that is covered is of significant interest to basic research scientists, clinicians and graduate students who are engaged in studying obesity-induced health complications. Furthermore, this book highlights the potential of novel approaches for the prevention and treatment of obesity and its related illnesses. Nineteen articles in this book are organized in four sections that are designed to provide an overview of obesity-induced health complications. The first section serves as an introductory section on the prevalence, causes, consequences, treatments and preventive approaches for obesity. Section two covers the metabolic disturbances and inflammation due to obesity. The third section is focused on neurological and visceral complications as a consequence of obesity. The final section covers strategies for the prevention of obesity-induced complications. The book illustrates that obesity can result in a diverse range of pathophysiological conditions that adversely affect health.
For most clinicians, the science and evidence for many integrative therapies is largely unknown or considered suspect. Most physicians don't have time to learn integrative approaches and aren't sure what to recommend or which approaches have merit or improved outcomes. In Integrative Preventive Medicine, clinicians have easy access to the best practices in integrative medicine and expectations for outcomes. The current state of the science is also presented. Authors are leaders in their fields, with decades of expertise and leadership in their fields.
Sleep was taking over Anna’s life. Despite multiple alarm clocks and powerful stimulants, the young Atlanta lawyer could sleep for thirty or even fifty hours at a stretch. She stopped working and began losing weight because she couldn’t stay awake long enough to eat. Anna’s doctors didn't know how to help her until they tried an oddball drug, connected with a hunch that something produced by her body was putting her to sleep. The Woman Who Couldn’t Wake Up tells Anna’s story—and the broader story of her diagnosis, idiopathic hypersomnia (IH), a shadowy sibling of narcolepsy that has emerged as a focus of sleep research and patient advocacy. Quinn Eastman explores the science around sleepiness, recounting how researchers have been searching for more than a century for the substances that tip the brain into slumber. He argues that investigation of IH could unlock new understandings of how sleep is regulated and controlled. Eastman foregrounds the experiences of people with IH, relating how publicity around Anna’s successful treatment helped others form a community. He shows how a group of patients who felt neglected or dismissed united to steer research toward their little-known disorder. Sharing emerging science and powerful stories, this book testifies to the significance of underrecognized diseases and sheds new light on how our brains function, day and night. It is essential reading for anyone interested in sleep and sleep disorders, including those affected by or seeking to treat them.